CytoDyn Inc.

08:12 23 Sep 2020

CytoDyn selected to make oral presentation at the "Special isirv-AVG Virtual Conference on Therapeutics for COVID-19"

CytoDyn Inc (OTCQB:CYDY), which is developing its flagship drug leronlimab (PRO 140) to battle multiple diseases, said Wednesday that its Phase 2 study of leronlimab for mild-to-moderate coronavirus (COVID-19) patients has been selected for an oral presentation at the upcoming "Special isirv-Antiviral Conference on Therapeutics for COVID-19."

The three-day conference starting on October 6 is sponsored by the UK-based International Society for Influenza and other Respiratory Virus Diseases.

"The acceptance of this oral abstract by this highly regarded scientific organization is very rewarding for all of the medical professionals who provided care and treatment to the COVID-19 patients during our Phase 2 trial," said CytoDyn CEO Nader Pourhassan.

"We also view this acceptance as a validation of leronlimab as a potential therapeutic for this disease and we look forward to the upcoming interim analysis from our Phase 3 trial for severe-to-critical COVID-19 patients."

READ: CytoDyn to meet with UK regulators to discuss Fast-Track approval for leronlimab, schedules sitdown with FDA

Vancouver, Washington-based CytoDyn completed its Phase 2 trial to evaluate the effectiveness and safety of leronlimab in patients with mild-to-moderate symptoms caused by COVID-19 infection in July this year.

Patients were randomized to receive weekly doses of 700 mg leronlimab, or placebo. Leronlimab and placebo were administered through injections. The patients receiving leronlimab experienced 64% fewer serious adverse events (SAEs) during the trial than patients receiving placebo

The Phase 2 clinical trial for mild-to-moderate patients in the US produced statistically significant results for NEWS2. Enrollment continues in CytoDyn's Phase 3 randomized clinical trial for severe-to-critically ill COVID-19 patients in several hospitals in the US. An interim analysis on the first 195 patients will be shared by mid-October.

Details of the presentation are as follows:

- Abstract Title: A Phase 2 Study of Leronlimab for mild-to-moderate coronavirus disease (COVID-19).
- Abstract Confirmation Number: AAVGV0010
- Presenter: Harish Seethamraju, medical director, Advanced Lung Failure and Lung Transplant, Montefiore Medical Center, Bronx, New York.
- Presentation Date: October 6-8, 2020
- Time: 12.00-4.00pm GMT and will be available on demand.

Price: 2.67

Market Cap: $1.52 billion

1 Year Share Price Graph



Share Information

Code:		CYDY
Listing:		OTCQB
52 week	**High**	**Low**
	10.01	**0.261**
Sector:		**Pharma & Biotech**
Website:		**www.cytodyn.com**

Company Synopsis:

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man.

action@proactiveinvestors.com

- Additional details can be found on the conference web site here

The FDA has granted Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars ($25,000).